CCL3 expression is significantly correlated with patient risk scores and levels of immune cell infiltration, which may affect disease progression and patient prognosis by modulating immune cell infiltration in the tumor microenvironment, potentially playing a role in immune evasion and progression of AML. Here, CCL3 is linked to neoplasm.